United Therapeutics CORP
Forward trial catalysts linked to UTHR
CSA tracks 1 forward catalyst for United Therapeutics CORP across 1 asset, spanning Phase 3. The nearest is a readout expected Dec 2026 (month precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include PAH.
UTHR in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, United Therapeutics CORP has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
1 trial behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| ralinepag | NCT03683186 catalyst | Phase 3 | Enrolling by invitation | 2026-12 | Experimental | United Therapeutics | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tis… |
Every trial the CSA sample links to UTHR's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →